AtheroGenics to Discontinue AGIX-4207 Pharmaceutical company AtheroGenics Inc. said Wednesday that a mid-stage trial to evaluate its AGIX-4207 treatment for rheumatoid arthritis failed to meet the study #39;s endpoint, showing no significant improvement compared with placebo. 

Which of the following sections of a newspaper would this article likely appear in? World News, Sports, Business, or Science and Technology? 